Background
==========

Hepatocellular carcinoma (HCC) is one of the leading etiologies of global cancer-related mortalities, which is especially prevalent in China.[@b1-cmar-9-525]--[@b4-cmar-9-525] Spontaneous tumor rupture (STR), which is an uncommon but potentially fatal complication of HCC, accompanied by intraperitoneal hemorrhage is a potentially fatal condition, with reported incidence ranging between 10% and 15%.[@b5-cmar-9-525]--[@b8-cmar-9-525]

When confronted with this condition, hemostasis should be urgently attempted as the initial treatment, followed by hepatic resection as secondary. Partial hepatectomy is a well-validated treatment strategy for HCC, which has become more feasible with satisfactory safety and efficacy profiles due to more advanced surgical technique and perioperative care. Partial hepatectomy is an effective treatment for spontaneously ruptured HCC, through which long-term survival can be achieved in selected patients.[@b9-cmar-9-525],[@b10-cmar-9-525] It should be performed when technically feasible as either an emergency or a staged operation (following embolization or other hemostatic procedures). However, the short- and long-term outcomes of patients undergoing partial hepatectomy due to spontaneous rupture of HCC warrant further validations.[@b3-cmar-9-525] The present study aimed to investigate the clinicopathological characteristics of ruptured HCC and to demonstrate the impact of tumor rupture and other prognostic factors on the prognosis of this condition in a large patient cohort.

Patients and methods
====================

This is a retrospective study of consecutive patients who underwent partial hepatectomy for HCC between April 2007 and November 2011 at the Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China. Data were prospectively collected in a computer database. Data analysis was done retrospectively. Additional data were obtained by reviewing medical records. The exclusion criteria were 1) incomplete clinical data; 2) presence of severe comorbidities that could affect life expectancy, such as with a history of severe cardiac disorders; 3) preoperative portal vein embolization; 4) surgical portosystemic shunts before or at the same time as hepatic resection, were treated as an emergency and 5) a palliative resection or had presented at pathologic examination. According to whether the HCC had ruptured or not, all participants were divided into two groups. Informed consent was obtained from all participants. The research protocol of this study was discussed and approved by the Clinical Research Ethics Committee of Eastern Hepatobiliary Surgery Hospital.

Preoperative care, surgical procedures and follow-up
----------------------------------------------------

Preoperative checkups, including electrocardiography, chest X-ray, complete blood counts, liver and renal function tests, serum α-fetoprotein (AFP) level, serological markers for hepatitis B and coagulation profile, were done for every patient. Tumor location and extent were assessed by computed tomography (CT) and/or magnetic resonance imaging (MRI), and resectability was determined accordingly. A previously described criterion was used for resection and remained identical over the study period.[@b11-cmar-9-525] Child--Pugh grade C liver function was considered as an absolute contraindication to partial hepatectomy.[@b12-cmar-9-525]

All operations were performed by experienced surgeons. Pringle manoeuver was routinely used with cycles of clamp/unclamp for 15/5 minutes. Transection of the hepatic parenchyma was done using the clamp-crushing technique, and hemostasis was done with suture ligations and argon beam coagulators. Anatomical resection was preferred when possible, while nonanatomical resection was reserved for tumors that were peripherally located or situated at the junction of several liver segments, as well as for patients with serious cirrhosis. Major hepatectomy was defined as resection of three or more Couinaud liver segments, while minor hepatectomy was defined as resection of fewer than three segments. The presence of cirrhosis was confirmed by histopathological examination.

When all microscopic and macroscopic tumors were resected, it was defined as R0 resection. A complication was defined as the occurrence of postoperative pulmonary, renal, cardiac or liver failure; biliary complications; sepsis of any etiology and wound complications. Ascites and pleural effusion that required diuretics or paracentesis were defined as morbidities. Postoperative liver failure was defined by a postoperative serum total bilirubin (TB) level of \>60 µmol/L, prothrombin time \>18 s and/or the development of postoperative hepatic encephalopathy. Postoperative conditions and complications were assessed daily from the day of surgery until discharge.

Patients were followed-up every 2--3 months during the first year after surgery and 3--6 months thereafter until November 30, 2016. All patients were followed up with AFP measurement, CT or MRI and chest X-ray at 4 weeks after operation for 6 months at a 2-month interval and every 3 months thereafter. Patients underwent positron emission tomography, digital subtraction angiography or bone scan when necessary. All follow-up examinations were done by two physicians blinded of patient information and study data. Diagnostic criteria for recurrences were the same as for preoperative diagnosis of HCC. Once recurrence occurred, treatment plan was made based on the pattern of recurrence, hepatic functional reserve and the patient's general condition. A multidisciplinary approach, including re-resection, local ablative therapy, transcatheter arterial chemoembolization (TACE), external irradiation, systemic chemotherapy/immunotherapy or sorafenib (since 2008), was adopted for patients with recurrence.

Special procedures for ruptured HCC
-----------------------------------

The diagnosis of HCC rupture was based on symptoms and signs upon admission, as well as bedside ultrasonography. For hemodynamically unstable patients, active resuscitation with intravascular fluid was initiated with correction of coagulopathy and patients were monitored closely in the ward or in the intensive care unit. In the majority of patients, bleeding would stop spontaneously with conservative treatment and watchful waiting. When the bleeding exacerbated, emergency transcatheter arterial embolization (TAE) was done. Some of the patients in this study had already undergone TAE before transferring to the authors' hospital for further treatment.

When bleeding could not be controlled by nonsurgical approaches, emergency laparotomy was indicated. For patients with resectable tumor, adequate liver functional reserves and satisfactory general condition, partial hepatectomy was conducted. Surgical hemostatic procedures, such as packing or hepatic artery ligation, suturing, plication and alcohol injection, were used to stop active bleeding at the site of rupture.

Pringle manoeuver and occlusion of the hepatic artery proper were used in emergency partial hepatectomy.[@b13-cmar-9-525] Tumor was reassessed for resectability after clot removal in the peritoneal cavity. Ideally, a resection margin of \>1 cm was planned. After hepatectomy, peritoneal lavage with distilled water (DWPL; 5000--10000 mL) was done, and 5-fluorouracil (5-FU; 500 mg) was left in the abdominal cavity before closure.[@b14-cmar-9-525]

Staged hepatectomy would be planned 2--6 weeks after the episode of spontaneous rupture for patients with resectable HCC whose bleeding had stopped either spontaneously or with laparotomy.

Statistical analysis
--------------------

All data are presented as mean values with standard deviation (SD) or percentages. Nominal data were compared with the Pearson *c*^2^ test; multiple forward stepwise logistic regressions were used when appropriate. The distribution of continuous data was tested using the Kolmogorov--Smirnov test; values are shown as mean (SD) if distributed normally and as median (range) otherwise. These data were analyzed by mean values of the independent samples *t*-test and Wilcoxon rank-sum test (Mann--Whitney *U*-test). Survival was calculated and compared with the log-rank test and presented with the Kaplan--Meier approach. Hospital mortality was defined as death during the hospital stay or within 60 days of surgery. Overall survival (OS) was defined as the length of time between surgery and death or the last follow-up examination. Recurrence-free survival (RFS) was calculated from the date of tumor resection until tumor recurrence or last observation. To identify factors predictive of survival, univariable and multivariable analyses were performed using the log-rank test and Cox proportional hazards model, respectively. All statistical analyses were conducted using SPSS software version 19.0 (IBM Corporation, Armonk, NY, USA). *P*\<0.05 was considered as statistically significant.

Results
=======

Characteristics of ruptured HCC
-------------------------------

During the study period, a total of 4209 patients with HCC were admitted in the authors' unit, of which 200 (4.8%) had tumor rupture. Of the 774 patients who underwent elective partial hepatectomy, 106 (13.7%) had STR before surgery ([Figure 1](#f1-cmar-9-525){ref-type="fig"}). Patients included in the study were divided into ruptured (n=106) and non-ruptured (n=201) groups. Both groups underwent hepatectomy from the same team of surgeons. In all, 94 patients with ruptured HCC did not receive hepatectomy due to various reasons: preoperative decision of unresectable HCC (51, 54.3%), intraoperative decision as not suitable for hepatectomy (4, 4.3%), inadequate liver functional reserve (17, 18.1%), poor general condition (10, 10.6%), patient refusal (3, 3.2%) or for undefined reasons (9, 9.5%).

A total of 99 men and seven women with a mean age of 47.9 years (range 22--75 years) were in the ruptured HCC group. No significant difference was found in age distributions and sex ratios between the ruptured and non-ruptured groups ([Table 1](#t1-cmar-9-525){ref-type="table"}). Sudden-onset abdominal pain (71 patients, 67%) and shock (54 patients, 51%) were more common in the ruptured HCC group. However, patients in the ruptured group presented with significantly more symptoms and higher prevalence of cirrhosis than those in the non-ruptured group. Meanwhile, patients in the ruptured group were more likely to have the presence of arterial hypertension (hypertension), ascites, higher Child--Pugh grade, a lower serum albumin level, a higher TB level, a higher serum AFP level, seropositivity for hepatitis B and worse tumor characteristics (including size,).

Perioperative outcomes
----------------------

Perioperative parameters, including macroscopic and microscopic findings, are summarized in [Table 2](#t2-cmar-9-525){ref-type="table"}. Tumor size in the ruptured HCC group was significantly greater than that in the non-ruptured group (*P*=0.002). Characteristics of the tumors, such as capsule formation, vascular invasion, satellite lesions, recurrence rate and surgical margins, were similar between the two groups. Patients with ruptured HCC were more likely to present with more intraoperative blood loss (*P*=0.006) and intraoperative blood transfusion (*P*\<0.001) but without a longer duration of operation (*P*=0.885) compared to those in the non-ruptured group. In addition, there was a lower R0 resection rate in the ruptured group (83.9% vs 87.6%). Patients with ruptured HCC were more likely to have a nonanatomical partial hepatectomy. No significant difference in morbidity and mortality was found between both groups ([Table 2](#t2-cmar-9-525){ref-type="table"}). One hospital death (due to hepatic failure) occurred in the ruptured group.

Factors associated with spontaneous rupture of HCC
--------------------------------------------------

Univariate analysis indicated that sudden-abdominal pain, underlying diseases of hypertension, liver cirrhosis, Child--Pugh grade, hemoglobin, TB, serum albumin level, AFP level, HBsAg, tumor size and ascites were significantly associated with STR ([Table 1](#t1-cmar-9-525){ref-type="table"}). That is, STR was more frequently observed in patients with sudden-abdominal pain, hypertension and cirrhosis, positive HBsAg, larger tumor size and a poorer liver functional reserve. However, STR was also more frequently observed in patients with the presence of ascites, a lower serum albumin level, a higher TB and AFP level.

Parameters associated with spontaneous rupture of HCC (multivariate analyses)
-----------------------------------------------------------------------------

Multivariate analysis with logistic regression revealed the following parameters as independent prognostic factors for STR: maximum tumor diameter (hazard ratio \[HR\]: 0.187 \[\>5 cm vs ≤5 cm\]), the presence of hypertension (HR: 0.036), liver cirrhosis (HR: 0.195), TB (HR: 0.373) and the presence of ascites (HR: 0.127; [Table 3](#t3-cmar-9-525){ref-type="table"}). Cox proportional hazards analyses of OS and RFS in 307 patients with HCC are shown in [Tables 4](#t4-cmar-9-525){ref-type="table"} and [5](#t5-cmar-9-525){ref-type="table"}.

Long-term survival outcomes
---------------------------

The duration of follow-up ranged from 1 to 104 months (median 35.9 months). Among the 307 surviving patients, 106 patients were in the ruptured group and 201 patients were in the non-ruptured group. The 1-, 3- and 5-year OS rates for all 307 patients were 54.0%, 37.3% and 33.8%, respectively, with a median OS of 17 months (95% confidence interval \[CI\]: 12.0--25.0). The 1-, 3- and 5-year OS rates for the 307 survivors who had an R0 resection were 88.8%, 64.6% and 53.7%, respectively, with a median OS of 41 months. The Kaplan--Meier survival curves of RFS and overall actuarial survival of both groups of patients are shown in [Figure 2](#f2-cmar-9-525){ref-type="fig"}. The median disease-free survival was 10 months (95% CI: 5.0--16.0) in the ruptured HCC group and 23 months (95% CI: 14.0--32.0) in the non-ruptured HCC group.

After partial hepatectomy, 92 (86.8%) of 106 patients in the ruptured group and 124 (61.7%) of 201 patients in the non-ruptured group died during follow-up. Peritoneal dissemination developed in 20 (7.5%) of 265 patients after R0 resection and occurred more often in the ruptured group: 29 (32.6%) of 89 patients versus nine (5.1%) of 176 patients (*P*\<0.001).

Impact of STR on survival
-------------------------

The ruptured HCC group had significantly lower OS rates (37.7%, 19.7% and 14.7% at 1, 3 and 5 years, respectively) than the non-ruptured HCC group (77.7%, 56.9% and 41.6%; *P*\<0.001; [Figure 2A](#f2-cmar-9-525){ref-type="fig"}). There was also a significant difference in RFS between the ruptured (45.8%, 34.2% and 31.3% at 1, 3 and 5 years, respectively) and non-ruptured (58.2%, 39.7% and 36.0%) groups (*P*=0.016; [Figure 2B](#f2-cmar-9-525){ref-type="fig"}).

Both univariable and multivariable analyses showed that STR was independently associated with poor OS (HR 1.89, 95% CI: 1.32--2.69). Furthermore, although univariable analyses showed that RFS was lower in the ruptured group than in the non-ruptured group (*P*=0.016), STR could not independently predict poor RFS after partial hepatectomy for HCC in multivariable analyses (HR 0.95, 95% CI: 0.64--1.41, *P*=0.782; [Tables S1](#SD1-cmar-9-525){ref-type="supplementary-material"} and [S2](#SD2-cmar-9-525){ref-type="supplementary-material"}).

Discussion
==========

The incidence of spontaneous rupture of HCC shows an obvious geographical difference in previously reported studies, and \~10%--15% of patients with HCC develop this complication.[@b7-cmar-9-525] In the present study, 106 (13.7%) of the 774 patients underwent hepatic resection due to HCC rupture.

In this study, we found a similar baseline characteristic between groups with and without rupture in physical findings, biochemical data, hepatitis status and extent of cirrhosis. Patients with ruptured HCC were more likely to have clinical manifestations such as sudden attack of severe abdominal pain, signs of bleeding during physical examination, a lower hemoglobin level, a larger tumor size, higher TB levels and greater intraoperative blood loss during hepatic resection.

Sudden abdominal pain in hemodynamic unstable HCC patients should indicate the diagnosis of ruptured HCC. Nevertheless, multiple logistic regression analysis did not confirm sudden-onset abdominal pain to be a prognostic factor in patients with ruptured HCC, which was not consistent with the study by Yeh et al.[@b10-cmar-9-525] A possible explanation may be that the patients enrolled in the present series were all treated in a single surgical team. Moreover, we found that STR was more frequent among patients with a larger tumor size and a poorer liver functional reserve (a higher serum TB level and presence of ascites), which is consistent with previous reports.[@b6-cmar-9-525],[@b15-cmar-9-525]

Interestingly, we also found the presence of hypertension and liver cirrhosis to be predictive factors for spontaneous rupture of HCC. It may be attributed to the fact that hypertension can directly result in an increase in pressure within the tumor; the rupture of a vascular tumor like HCC may thus lead to the tearing of vessels with uncontrollable blood loss. The condition may be further exacerbated in cirrhotic patients with underlying coagulopathy. Both of the two factors may promote the process of rupture described earlier.[@b16-cmar-9-525]

Treatments for ruptured HCC include control of hemorrhage and liver resection when possible. The feasibility of hepatectomy depends largely on the extent of the tumor (e.g., caval involvement). Hepatic resection is technically challenging in cirrhotic livers. Lai et al[@b17-cmar-9-525] reported that 60.7% of patients with ruptured HCC had macroscopic cirrhosis, and only 12.5% of patients were managed by hepatectomy. Dewar et al[@b18-cmar-9-525] reported that 36 of 37 patients with ruptured HCC had underlying cirrhosis of the liver, 11 of whom underwent hepatectomy. In our study, 89 of the 106 patients with ruptured HCC had underlying cirrhosis, and over half of the patients (60.4%, 64/106) underwent resection. With recent improvements in hepatic surgery, hepatectomy for ruptured HCC is feasible and may be potentially curative.

Previous Japanese[@b19-cmar-9-525] and Italian[@b20-cmar-9-525] studies have confirmed that emergency hepatic resection for ruptured HCC may achieve a long-term outcome comparable with that of elective surgery in selected patients. We also demonstrated that patients with ruptured HCC who underwent hepatectomy had worse OS compared with those in the non-ruptured HCC group.

Although it is generally presumed that STR is a risk factor impacting the prognosis of HCC patients undergoing hepatic resection, controversies remain on this issue.[@b9-cmar-9-525],[@b10-cmar-9-525],[@b21-cmar-9-525] For instance, Aoki et al[@b6-cmar-9-525] and Liu et al[@b9-cmar-9-525] reported that the survival of patients with ruptured HCC was significantly worse than that of patients with non-ruptured HCC. In contrast, Yeh et al[@b10-cmar-9-525] reported that patients with ruptured HCC had a similar OS compared to those with non-ruptured HCC; however, disease-free survival rate was significantly lower in those with ruptured HCC. As observed elsewhere,[@b19-cmar-9-525] a trend toward lower disease-free survival rate was observed in patients with tumor rupture who underwent hepatic resection. The present study has identified in a large patient cohort that tumor rupture itself had a negative impact on patient survival; furthermore, of note, STR, which was not independently associated with poorer RFS (HR 0.95, 0.64--1.41) after hepatectomy, predicted poor OS and RFS after hepatectomy for HCC.

It is worth pointing out that all surgeons in our unit had abundant operating experience of hepatectomies. As a result, the rate of hepatectomy in the present cohort was much higher than previous counterparts.[@b9-cmar-9-525],[@b20-cmar-9-525] The 1-, 3- and 5-year OS and RFS rates after hepatectomy for ruptured HCC were comparable with those reported elsewhere.[@b9-cmar-9-525],[@b10-cmar-9-525],[@b22-cmar-9-525]

Perioperative morbidity and mortality rates were comparable between both groups, suggesting that hepatectomy did not pose additional perioperative risk for ruptured HCC in selected patients whose operations were performed by experienced surgeons. Peritoneal dissemination is not uncommon after curative resection of ruptured HCC;[@b22-cmar-9-525] DWPL and intraperitoneal 5-FU were thus administered to prevent peritoneal dissemination. DWPL would remove tumor cells to a large extent, and thus, tumor recurrence would be delayed and better survival would be achieved in patients with spontaneously ruptured HCCs.[@b14-cmar-9-525],[@b23-cmar-9-525] Currently, the role of 5-FU in HCC treatment regarding adjuvant therapy after surgery, based on a randomized, controlled trial, placebo controlled,[@b24-cmar-9-525] that showed lower recurrence rate and higher time-to-tumor progression as well as 5-year OS was better in the 5-FU group. In addition to the tumors being more advanced in the ruptured group, the R0 resection rate was significantly lower than that in the non-ruptured group (83.9% vs 87.6 %). In some patients with ruptured HCC, the intraoperative extent of tumor was more advanced than on preoperative assessment, with intraperitoneal seeding being detected at operation. Finally, peritoneal secondaries were more often found on follow-up in the ruptured group after R0 resection.

Yamagata et al[@b19-cmar-9-525] claimed that increased intratumor pressure with venous invasion was the main culprit for recurrence in the ruptured HCC. However, in the present series, a similar percentage of vascular invasion was observed between ruptured and non-ruptured groups. Greater blood loss and more blood transfusion needs might contribute to the poorer disease-free survival in patients with ruptured HCC. Perioperative blood transfusion has been related to shorter disease-free survival because of the immunosuppressive effect of transfusion.[@b25-cmar-9-525]

Battula et al[@b26-cmar-9-525] reported that the multifocality of the tumor and large tumor size can help predict the risk of decompensation and poor outcomes. Kirikoshi et al[@b27-cmar-9-525] demonstrated that tumor size was the only independent factor for long-term survival among patients who underwent successful initial TAE. In the present series, tumor size was an important factor influencing survival in patients undergoing successful hepatectomy for ruptured HCC; moreover, we identified that tumor size was an independent factor influencing OS (HR: 1.74, 95% CI: 1.21--2.49, *P*=0.003) and RFS (HR: 1.99, 95% CI: 1.35--2.93, *P*=0.001).

In addition, the present study, together with the studies of Sun et al[@b28-cmar-9-525] and Hung et al,[@b29-cmar-9-525] showed that hepatitis B positivity was an independent factor for OS and disease-free survival and was associated with a higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B virus (HBV)-related HCC (within 1 year),[@b28-cmar-9-525]--[@b30-cmar-9-525] suggesting HBsAg positivity impact on OS and RFS after partial hepatectomy for HCC. Although there was not a significant difference in OS or RFS between the ruptured and non-ruptured groups, the HBsAg-negative group had lower OS rates (63.2%, 45.6% and 42.1% at 1, 3 and 5 years respectively) than the HBsAg-positive group (52.1%, 35.4%, 32%); meanwhile, the 1-, 3-, 5-year OS rates for HBsAg-negative patients were 70.5%, 54.4% and 43.1%, respectively, in contrast to 62.7%, 42.2% and 30.2% for HBsAg-positive patients.

The present study has several flaws. First, although the data were collected prospectively, this is actually a retrospective cohort study with all its inherent shortcomings. Second, the study population in the present study was limited to Chinese HCC patients and the dominant etiology of the liver disease was HBV, which is different from that seen in Western countries.

Conclusion
==========

The presence of hypertension, liver cirrhosis, higher serum TB level, tumor size \>5cm and ascites are the independent indicators of ruptured HCC. The present study confirmed that tumor rupture itself had a negative impact on patient survival, and hepatic resection for patients with spontaneous HCC rupture is often feasible and is the treatment of choice for ruptured HCC, which can result in OS and RFS rates that are comparable to those of patients without rupture.

Supplementary materials
=======================

###### 

Univariable and multivariable analyses of overall survival in 307 patients with hepatocellular carcinoma

  Variable                        n     Overall survival (%)   Univariable *P*[\#](#tfn11-cmar-9-525){ref-type="table-fn"}   Multivariable *P*[\*](#tfn12-cmar-9-525){ref-type="table-fn"}   Hazard ratio             
  ------------------------------- ----- ---------------------- ------------------------------------------------------------- --------------------------------------------------------------- -------------- --------- -------------------
  Sex                                                                                                                                                                                                                 
   Male                           278   63.4                   43.3                                                          31.7                                                            0.403                    
   Female                         29    69.0                   51.7                                                          37.9                                                                                     
  Age (years)                                                                                                                                                                                                         
   \<60                           255   62.4                   42.3                                                          33.8                                                            0.929                    
   ≥60                            52    71.7                   52.8                                                          25.0                                                                                     
  Presentation                                                                                                                                                                                                        
   Subclinical                    149   87.9                   66.0                                                          54.9                                                            0.016          0.184     
   Symptomatic                    158   79.2                   48.5                                                          39.7                                                                                     
  HBsAg                                                                                                                                                                                                               
   Positive                       263   62.7                   42.2                                                          30.2                                                            0.062                    
   Negative                       44    70.5                   54.4                                                          43.1                                                                                     
  TB (µmol/L)                                                                                                                                                                                                         
  \<18.8                          192   68.2                   49.0                                                          37.7                                                            0.007          0.871     
  ≥18.8                           115   56.9                   36.0                                                          23.0                                                                                     
  α-Fetoprotein (mg/L)                                                                                                                                                                                                
   \<400                          146   80.8                   58.8                                                          43.9                                                            \<0.001        0.002     1.59 (1.18, 2.15)
   ≥400                           161   48.8                   30.9                                                          22.0                                                                                     
  PT (s)                                                                                                                                                                                                              
  \<13                            149   63.1                   40.3                                                          31.8                                                            0.938                    
  ≥13                             158   64.8                   47.7                                                          32.7                                                                                     
  Child--Pugh grade                                                                                                                                                                                                   
   A                              295   64.9                   44.5                                                          32.3                                                            \<0.001        0.044     0.43 (0.19, 0.98)
   B                              12    41.7                   33.3                                                          27.5                                                                                     
  Cirrhosis                                                                                                                                                                                                           
   Yes                            105   67.6                   48.6                                                          34.9                                                            0.385                    
   No                             202   62.1                   41.8                                                          31.0                                                                                     
  ALT (units/L)                                                                                                                                                                                                       
   \<40                           133   60.9                   47.3                                                          35.4                                                            0.387                    
   ≥40                            174   66.3                   41.7                                                          30.0                                                                                     
  AST (units/L)                                                                                                                                                                                                       
   \<40                           103   73.8                   56.2                                                          44.8                                                            0.008          0.326     
    ≥40                           204   59.0                   38.0                                                          26.0                                                                                     
  Spontaneous tumor rupture                                                                                                                                                                                           
   Yes                            106   37.7                   19.7                                                          14.7                                                            \<0.001        \<0.001   1.89 (1.32, 2.69)
   No                             201   77.7                   56.9                                                          41.6                                                                                     
  Maximum tumor size (cm)                                                                                                                                                                                             
   \<5                            103   88.3                   67.9                                                          52.9                                                            \<0.001        0.003     1.74 (1.21, 2.49)
   ≥5                             204   51.7                   32.2                                                          21.9                                                                                     
  Macroscopic vascular invasion                                                                                                                                                                                       
   Yes                            125   45.2                   12.9                                                          5.7                                                             \<0.001        0.806     
   No                             182   64.5                   45.8                                                          35.7                                                                                     
  Microscopic vascular invasion                                                                                                                                                                                       
   Yes                            272   27.8                   11.1                                                          8.3                                                             \<0.001        \<0.001   2.30 (1.53, 3.46)
   No                             35    68.7                   48.5                                                          35.5                                                                                     
  Extrahepatic spread                                                                                                                                                                                                 
   Yes                            67    41.2                   26.5                                                          20.6                                                            \<0.001        0.155     
   No                             240   70.4                   49.1                                                          35.7                                                                                     
  Tumor differentiation                                                                                                                                                                                               
   I--II                          45    92.5                   77.0                                                          66.9                                                            \<0.001        0.080     
   III--IV                        262   79.7                   53.1                                                          43.3                                                                                     
  Tumor type                                                                                                                                                                                                          
   Unifocal                       242   70.2                   50.4                                                          36.6                                                            \<0.001        0.002     1.69 (1.22, 2.36)
   Multiple/diffuse               65    40.9                   21.2                                                          16.4                                                                                     
  Blood loss (mL)                                                                                                                                                                                                     
   \<500                          200   86.5                   65.9                                                          56.2                                                            0.004          0.084     
   ≥500                           107   72.0                   40.0                                                          29.0                                                                                     
  Blood transfusion                                                                                                                                                                                                   
   Yes                            83    66.7                   34.0                                                          23.2                                                            \<0.001        0.221     
   No                             224   87.8                   65.6                                                          55.9                                                                                     
  Type of hepatectomy                                                                                                                                                                                                 
   Anatomical                     189   82.4                   57.5                                                          47.0                                                            0.600                    
   Non-anatomical                 118   81.1                   54.9                                                          46.0                                                                                     
  Extent of hepatectomy                                                                                                                                                                                               
   Major                          163   80.0                   54.8                                                          44.2                                                            0.130                    
   Minor                          144   85.1                   60.0                                                          47.3                                                                                     
  Surgical resection margin                                                                                                                                                                                           
   R0                             265   88.8                   64.6                                                          53.7                                                            \<0.001        0.057     
   R1                             40    43.8                   9.8                                                           5.8                                                                                      
   R2                             2     18.9                   4.9                                                           2.0                                                                                      

**Notes:** Values in parentheses are 95% confidence intervals.

Log rank test.

Variables with univariable *P*\<0.05 were entered in the Cox regression model.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PT, prothrombin time; TB, total bilirubin.

###### 

Univariable and multivariable analyses of recurrence-free survival in 307 patients with hepatocellular carcinoma

  Variable                           n     Recurrence-free survival (%)   Univariable *P*[\#](#tfn15-cmar-9-525){ref-type="table-fn"}   Multivariable *P*[\*](#tfn16-cmar-9-525){ref-type="table-fn"}   Hazard ratio           
  ---------------------------------- ----- ------------------------------ ------------------------------------------------------------- --------------------------------------------------------------- -------------- ------- -------------------
  Sex                                                                                                                                                                                                                          
   Male                              278   53.5                           36.3                                                          33.1                                                            0.566                  
   Female                            29    58.2                           45.8                                                          38.8                                                                                   
  Age (years)                                                                                                                                                                                                                  
   \<60                              255   52.7                           37.4                                                          34.0                                                            0.778                  
   ≥60                               52    59.8                           36.3                                                          31.7                                                                                   
  Presentation                                                                                                                                                                                                                 
   Subclinical                       159   80.1                           59.5                                                          43.5                                                            \<0.001        0.095   
   Symptomatic                       148   65.4                           44.3                                                          29.0                                                                                   
  HBsAg                                                                                                                                                                                                                        
   Positive                          263   52.1                           35.4                                                          32.0                                                            0.139                  
   Negative                          44    63.2                           45.6                                                          42.1                                                                                   
  TB (µmol/L)                                                                                                                                                                                                                  
   \<18.8                            192   49.1                           30.3                                                          28.6                                                            0.157                  
   ≥18.8                             115   56.8                           41.1                                                          36.7                                                                                   
  α-Fetoprotein (mg/L)                                                                                                                                                                                                         
   \<400                             145   66.6                           45.0                                                          40.2                                                            \<0.001        0.026   1.45 (1.04, 2.01)
   ≥400                              162   41.4                           29.8                                                          27.7                                                                                   
  PT (s)                                                                                                                                                                                                                       
   \<13                              149   56.4                           39.4                                                          36.3                                                            0.580                  
   ≥13                               158   51.9                           36.2                                                          31.5                                                                                   
  Child--Pugh grade                                                                                                                                                                                                            
   A                                 295   54.1                           37.0                                                          33.4                                                            0.738                  
   B                                 12    48.6                           30.2                                                          20.2                                                                                   
  Cirrhosis                                                                                                                                                                                                                    
   Yes                               202   51.4                           35.8                                                          32.2                                                            0.740                  
   No                                105   58.7                           38.4                                                          35.0                                                                                   
  ALT (units/L)                                                                                                                                                                                                                
   \<40                              133   54.9                           39.5                                                          34.2                                                            0.899                  
   ≥40                               174   52.6                           35.5                                                          33.7                                                                                   
  AST (units/L)                                                                                                                                                                                                                
   \<40                              103   65.9                           46.0                                                          40.5                                                            0.029          0.326   
   ≥40                               204   54.3                           34.8                                                          30.5                                                                                   
  Spontaneous tumor rupture                                                                                                                                                                                                    
   Yes                               106   45.8                           34.2                                                          31.3                                                            0.016          0.782   0.95 (0.64, 1.41)
   No                                201   58.2                           39.7                                                          36.0                                                                                   
  Maximum tumor size (cm)                                                                                                                                                                                                      
   \<5                               103   78.1                           52.4                                                          50.1                                                            \<0.001        0.001   1.99 (1.35, 2.93)
   ≥5                                204   40.6                           29.8                                                          24.4                                                                                   
  Macroscopic vascular invasion                                                                                                                                                                                                
   Yes                               124   55.1                           34.6                                                          2                                                               0.664                  
   No                                183   53.1                           32.9                                                          45                                                                                     
  Microscopic vascular invasion                                                                                                                                                                                                
   Yes                               270   10.4                           10.1                                                          6.9                                                             \<0.001        0.002   2.01 (1.29, 3.12)
   No                                37    59.2                           40.5                                                          37.1                                                                                   
  Extrahepatic spread                                                                                                                                                                                                          
   Yes                               68    35.7                           27.0                                                          19.2                                                            \<0.001        0.064   
   No                                239   58.9                           40.1                                                          37.6                                                                                   
  Tumor differentiation                                                                                                                                                                                                        
   I--II                             50    85.0                           72.0                                                          67.0                                                            \<0.001        0.511   
   III--IV                           257   66.0                           44.2                                                          35.4                                                                                   
  Tumor type                                                                                                                                                                                                                   
   Unifocal                          242   58.8                           40.9                                                          37.0                                                            \<0.001        0.661   
   Multiple/diffuse                  65    35.5                           23.7                                                          21.7                                                                                   
  Perioperative blood loss (mL)                                                                                                                                                                                                
   \<500                             209   75.2                           56.0                                                          46.0                                                            \<0.001        0.165   
   ≥500                              98    58.0                           34.5                                                          28.7                                                                                   
  Intraoperative blood transfusion                                                                                                                                                                                             
   Yes                               76    53.0                           30.2                                                          22.5                                                            \<0.001        0.057   
   No                                231   74.5                           54.9                                                          45.4                                                                                   
  Type of hepatectomy                                                                                                                                                                                                          
   Anatomical                        189   68.8                           49.4                                                          40.2                                                            0.899                  
   Non-anatomical                    118   68.6                           48.9                                                          40.8                                                                                   
  Extent of hepatectomy                                                                                                                                                                                                        
   Major                             163   61.9                           44.0                                                          31.0                                                            0.079                  
   Minor                             144   70.5                           50.9                                                          41.6                                                                                   

**Notes:** Values in parentheses are 95% confidence intervals.

Log rank test.

Variables with univariable *P*\<0.05 were entered in the Cox regression model.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PT, prothrombin time; TB, total bilirubin.
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![Study flow chart.\
**Abbreviation:** HCC, hepatocellular carcinoma.](cmar-9-525Fig1){#f1-cmar-9-525}

![(**A**) OS and (**B**) RFS after hepatectomy for ruptured and non-ruptured HCC.\
**Note:** (**A** and **B**) *P*\<0.001 (log-rank test).\
**Abbreviations:** HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival.](cmar-9-525Fig2){#f2-cmar-9-525}

###### 

Demographic and laboratory data for patients with ruptured and non-ruptured HCC undergoing hepatectomy

  Variables                   Ruptured HCC (n=106)   Non-ruptured HCC (n=201)   *P*-value
  --------------------------- ---------------------- -------------------------- ----------------------------------------------------
  Age (years)                 47.9 (22--75)          50.5 (21--78)              0.066
  Sex (M:F)                   99/7                   179/22                     0.216
  Diabetes                    3/103                  5/196                      0.858
  Hypertension                10/96                  6/195                      0.016[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Liver cirrhosis             89/17                  113/88                     \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Child--Pugh (A:B)           96/10                  199/2                      \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  PT (s)                      13.0 (10.4--17.8)      13.3 (9.8--23.5)           0.165
  Hemoglobin (g/L)            126 (60--141)          140 (90--155)              \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  TB (µmol/L)                 21.8 (6.3--130)        16.1 (5.2--48.3)           \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Albumin (g/L)               39.7 (23.2--49.4)      40.8 (24.7--55.5)          0.029[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  ALT (IU/L)                  60.3 (9.1--559.8)      59.4 (9.6--411.4)          0.892
  AST (IU/L)                  67.9 (12.4--785.1)     59.9 (17.3--353.5)         0.280
  Creatinine (µmol/L)         71.9 (39--103)         74.4 (35--242)             0.223
  AFP (µg/L)                  643.3 (1.5--1000)      771.7 (2--63159)           0.768
  AFP \>100 µg/L              75/31                  113/88                     0.013[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Positive HBsAg              98/8                   164/37                     0.013[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Tumor size (cm)             8.6 (1.8--17.5)        7.1 (1--22)                0.002[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Tumor size \>5 cm           89/17                  116/85                     \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}
  Tumor location (R/L/both)   72/24/10               145/38/18                  0.715
  Protrusion                  55/51                  90/111                     0.235
  Vascular thrombus           61/45                  121/80                     0.653
  Capsule formation           64/42                  130/71                     0.459
  Satellite lesions           23/83                  35/166                     0.362
  Ascites                     51/55                  16/185                     \<0.001[\*](#tfn2-cmar-9-525){ref-type="table-fn"}

**Notes:** Data presented as ratio or mean value (range minimum to maximum).

*P*\<0.05.

**Abbreviations:** AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, female; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; L, left; M, male; PT, prothrombin time; R, right; TB, total bilirubin.

###### 

Operative detail of patients with ruptured and non-ruptured HCC undergoing hepatectomy

  Detail                        Ruptured HCC (n=106)   Non-ruptured HCC (n=201)   *P*-value
  ----------------------------- ---------------------- -------------------------- ----------------------------------------------------
  Extent of hepatectomy                                                           0.169
   Minor                        44                     100                        
   Major                        62                     101                        
  Type of hepatectomy                                                             0.022[\*](#tfn5-cmar-9-525){ref-type="table-fn"}
   Anatomical                   56                     133                        
   Nonanatomical                50                     68                         
  Operating time (min)          166.8±70.2             165.6±69.0                 0.885
  Duration of clamping (min)    17.1±8.5               16.0±7.3                   0.233
  Blood loss (mL)               819.8±987.0            521.3±779.5                0.006[\*](#tfn5-cmar-9-525){ref-type="table-fn"}
  Blood transfusion (mL)        876.1±1237.8           371.4±1048.5               \<0.001[\*](#tfn5-cmar-9-525){ref-type="table-fn"}
  Margin \>1 cm                 7/99                   26/175                     0.089
  Surgical margins                                                                0.655
   R0 resection                 89                     176                        
   R1 resection                 16                     24                         
   R2 resection                 1                      1                          
  Hospital death                1                      1                          0.644
  Major complications                                                             
   Postoperative bleeding       0                      1                          0.467
   Liver failure                1                      2                          0.239
   Bile leak                    1                      3                          0.687
   Pleural effusion             51                     106                        0.441
  Postoperative hospital stay   20.2±7.3               18.6±7.4                   0.083
  Recurrence                    57/49                  124/77                     0.183

**Notes:** Data presented as number or mean ± SD.

*P*\<0.05.

###### 

Multiple forward stepwise logistic regression analysis of clinicopathological features

  Variables                               SE      Wald     HR      95% CI for HR   *P*-value
  --------------------------------------- ------- -------- ------- --------------- ----------------------------------------------------
  Hypertension (presence vs absence)      0.817   16.451   0.036   0.01--0.18      \<0.001[\*](#tfn6-cmar-9-525){ref-type="table-fn"}
  Liver cirrhosis (presence vs absence)   0.384   18.142   0.195   0.09--0.41      \<0.001[\*](#tfn6-cmar-9-525){ref-type="table-fn"}
  Tumor size (≤5 vs \>5 cm)               0.380   19.516   0.187   0.09--0.39      \<0.001[\*](#tfn6-cmar-9-525){ref-type="table-fn"}
  TB (≤18.8 vs \>18.8 µmol/L)             0.314   9.866    0.373   0.20--0.69      0.002[\*](#tfn6-cmar-9-525){ref-type="table-fn"}
  Ascites (presence vs absence)           0.393   27.499   0.127   0.06--0.28      \<0.001[\*](#tfn6-cmar-9-525){ref-type="table-fn"}

**Note:**

*P*\<0.05.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; SE, standard error; TB, total bilirubin.

###### 

Cox proportional hazards analyses of OS in 307 patients with HCC

  Variables                                   SE      Wald     Exp(*B*)   95% CI         *P*-value
  ------------------------------------------- ------- -------- ---------- -------------- -----------
  Maximum tumor size (≥5 vs \<5 cm)           0.183   9.047    1.736      1.212--2.486   0.003
  AFP (≥400 vs \<400 µg/L)                    0.153   9.251    1.591      1.179--2.145   0.002
  Tumor type (unifocal vs multiple/diffuse)   0.169   9.704    1.692      1.215--2.355   0.002
  Microscopic vascular invasion (yes vs no)   0.208   16.134   2.302      1.533--3.459   \<0.001
  Child--Pugh grade (A vs B)                  0.417   4.068    0.431      0.190--0.977   0.044
  STR (yes vs no)                             0.181   12.328   1.889      1.324--2.694   \<0.001

**Abbreviations:** AFP, α-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival; SE, standard error; STR, spontaneous tumor rupture.

###### 

Cox proportional hazards analyses of RFS in 307 patients with HCC

  Variables                                   SE      Wald     Exp(*B*)   95% CI         *P*-value
  ------------------------------------------- ------- -------- ---------- -------------- -----------
  Maximum tumor size (≥5 vs \<5 cm)           0.198   12.022   1.985      1.347--2.926   0.001
  AFP (≥400 vs \<400 µg/L)                    0.167   4.927    1.448      1.044--2.009   0.026
  Microscopic vascular invasion (yes vs no)   0.225   9.622    2.009      1.293--3.121   0.002
  STR (yes vs no)                             0.203   0.077    0.945      0.635--1.407   0.782

**Abbreviations:** AFP, α-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; RFS, recurrence-free survival; SE, standard error; STR, spontaneous tumor rupture.
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